刘燕青,黄健,黄韻祝,娄方方,孔维莹
LIU Yanqing,HUANG Jian,HUANG Yunzhu,LOU Fangfang,KONG Weiying

• 1:贵州医科大学医学检验学院
• 2:贵州医科大学
• 3:贵州医科大学附院生化科

摘要(Abstract)：

目的:构建组蛋白去乙酰化酶2(HDAC2)基因RNA慢病毒干扰质粒载体。方法:对比HDAC2基因序列,设计并合成短发夹RNA(shRNA)干扰靶点序列,克隆入经Age I与EcoRI双酶切后的RNA干扰载体p LKO.1-puro,构建p LKO.1-HDAC2-shRNA重组质粒,采用酶切法和测序法验证重组质粒。结果:成功退火合成3对短发夹RNA序列并将其克隆入p LKO.1-puro载体中,构建重组质粒p LKO.1-HDAC2-shRNA1、p LKO.1-HDAC2-shRNA2及p LKO.1-HDAC2-shRNA3,经酶切鉴定和测序验证重组质粒载体与预期靶序列相同。结论:成功构建HDAC2-shRNA慢病毒干扰载体,为进一步研究HDAC2的功能及应用提供有效工具。
Objective: To construct a lentivirus vector for RNA interference of HDAC2 gene. Methods: The shRNA interference sequences targeting human HDAC2 gene were designed,synthesized,and then ligated with the linearized p LKO. 1-puro vector which had been digested with the Age I and EcoRI,then the p LKO. 1-HDAC2-shRNA recombinant lentiviral vectors were constructed and confirmed by enzyme digestion and DNA sequencing. Results: 3 pairs of synthesized short hairpin RNA sequences were successfully annealed and cloned into p LKO. 1-puro vector to construct recombinant plasmid p LKO. 1-HDAC2-shRNA1,p LKO. 1-HDAC2-shRNA2,p LKO. 1-HDAC2-shRNA3. Enzyme digestion and DNA sequencing confirmed that the sequence in the recombinant plasmid vector was the same as the target sequence,which meaned three shRNA recmbinant lentiviral plasmid vectors were successfully constructed. Conclusion: Three shRNA recmbinant lentiviral plasmid vectors are successfully constructed and provide an effective tool for further study of function and clinical application of HDAC2 gene.

关键词(KeyWords)： 组蛋白去乙酰化酶2;RNA干扰;慢病毒载体;质粒;DNA,重组
histone deacetylase 2;RNA interference;lentivirus vector;plasmid;DNA,recommbinant

Abstract:

Keywords:

基金项目(Foundation): 贵州省联合基金[黔科合LH字(2014)7114]

作者(Author): 刘燕青,黄健,黄韻祝,娄方方,孔维莹
LIU Yanqing,HUANG Jian,HUANG Yunzhu,LOU Fangfang,KONG Weiying

DOI: 10.19367/j.cnki.1000-2707.2015.07.007

参考文献(References)：

• [1]Wang SS,Li XM,Parra M,et al.Control of endothelial cell proliferation and migrationby VEGF signaling to histone deacetylase[J].Proc Natl Acad Sci USA,2008(22):7738-7743.
• [2]王继峰.RNAi基因沉默技术[J].中国生物化学与分子生物学会中医药专业委员会年年会文集,2005(1):29-37.
• [3]Krmer OH.HDAC2:a critical factor in health and disease[J].Trends Pharmacol Sci,2009(12):647-655.
• [4]Hayashi A,Horiuehi A,Kikuchi N,et al.Type-specific roles of histone deacetylase HDAC overexpression in ovarian carcinoma:HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with down-regulation of E-cadherin[J].Int J Cancer,2010(6):1332-1346.
• [5]Liu T,Xu F,Du X,et al.Establishment and characterization of multidrug resistant,prostate carcinoma-initiating stem like cells from human prostate cancer cell lines22RV[J].Mol Cell Biochem,2010(12):265-273.
• [6]Zhu P,Martin E,Menqwasser J,et al.Induction of HDAC2expression upon loss of APC in colorectal tumorigenesis[J].Cancer Cell,2004(5):455-463.
• [7]Fritsche P,Seidler B,Schüler S,et al.HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA[J].Gut,2009(10):1399-1409.
• [8]Ropero S,Ballestar E,Alaminos M,et al.Transforming pathways unleashed by a HDAC2 mutation in human cancer.Oncogene,2008(27):4008-4012.
• [9]Ashihara E,Kawata E,Maekawa.Future prospect of RNA interference for cancer therapies[J].Curr Drug Targets,2010(3):345-360.
• [10]蔡明俊,雷霆,郭东生.RNA干扰技术在胶质瘤治疗中的应用[J].中国临床神经外科杂志,2007(5):319-321.

文章评论(Comment)：